Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 2 51-2, 2005, Pages

  Radu, Razvan Gheorghe ^a   Fujimoto, Shimpei ^a   Mukai, Eri ^a   Takehiro, Mihoko ^a   Shimono, Dai ^a   Nabe, Koichiro ^a   Shimodahira, Makiko ^a   Kominato, Rieko ^a   Aramaki, Yo ^a   Nishi, Yuichi ^a   Funakoshi, Shogo ^a   Yamada, Yuichiro ^a   Seino, Yutaka ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KANSAI DENRYOKU HOSPITAL   (Japan)

Author keywords

Adenosine 5 triphosphate; Islet

Indexed keywords

2 OXOISOCAPROIC ACID; ADENOSINE TRIPHOSPHATE; DNA; GLUCOKINASE; GLUCOSE; HEXOKINASE; INSULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TACROLIMUS;

ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DNA CONTENT; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; FLUORESCENCE; GLUCOSE UTILIZATION; INSULIN RELEASE; MALE; MITOCHONDRION; NONHUMAN; NUCLEOTIDE METABOLISM; PANCREAS ISLET; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUCOKINASE; GLUCOSE; INSULIN; ISLETS OF LANGERHANS; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR;

EID: 19944427094     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00390.2004     Document Type: Article

References (42)

1. Aizawa T, Komatsu M, Asanuma N, Sato Y, and Sharp GWG. Glucose action "beyond ionic events" in the pancreatic β cell. Trends Pharmacol Sci 19: 496-499, 1998.
2. Ashcroft SJ, Weerasinghe LC, Bassett JM, and Randle PJ. The pentose cycle and insulin release in mouse pancreatic islets. Biochem J 126: 525-532, 1972.
3. Busuttil RW and Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 77: S44-S51, 2004.
4. Detimary P, Jonas JC, and Henquin JC. Stable and diffusible pools of nucleotides in pancreatic islet cells. Endocrinology 137: 4671-4676, 1996.
5. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, and Papadimitriou JC. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 68: 396-402, 1999.
6. Filler G, Neuschulz I, Vollmer I, Amendt P, and Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 15: 867-871, 2000.
7. Fruman DA, Klee CB, Bierer BE, and Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 89: 3686-3690, 1992.
8. 2+ sensitivity in β-cells. Endocrinology 139: 1133-1140, 1998.
9. Fujimoto S, Mukai E, Hamamoto Y, Takeda T, Takehiro M, Yamada Y, and Seino Y. Prior exposure to high glucose augments depolarization-induced insulin release by mitigating the decline of ATP level in rat islets. Endocrinology 143: 213-221, 2002.
10. Fujimoto S, Tsuura Y, Ishida H, Tsuji K, Mukai E, Kajikawa M, Hamamoto Y, Takeda T, Yamada Y, and Seino Y. Augmentation of basal insulin release from rat islets by preexposure to a high concentration of glucose. Am J Physiol Endocrinol Metab 279: E927-E940, 2000.
11. Gao Z, Young RA, Li G, Najafi H, Buettger C, Sukumvanich SS, Wong RK, Wolf BA, and Matschinsky FM. Distinguishing features of leucine and α-ketoisocaproate sensing in pancreatic β-cells. Endocrinology 144: 1949-1957, 2003.
12. + channels in mouse B cells. J Clin Invest 89: 1288-1295, 1992.
13. 2+ concentration in an electrically excitable cell, the insulin-secreting pancreatic B-cell. J Biol Chem 267: 20713-20720, 1992.
14. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760, 2000.
15. Hirano Y, Fujihira S, Ohara K, Katsuki S, and Noguchi H. Morphological and functional changes of islets of Langerhans in FK-506-treated rats. Transplantation 53: 889-894, 1992.
16. Jain AB, Fung JJ, Todo S, Reyes J, Selby R, Irish W, Doyle H, Abu-Elmagd K, Casavilla A, Nour B, Bronsther O, Jabbour N, Pinna A, Dodson F, Ramos H, McMichael JJ, McCauley J, Tzakis AG, Marino I, Marsh W, Venkataramanan R, Iwatsuki S, and Starzl TE. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc 27: 1099-1104, 1995.
17. 2+-responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol 15: 1758-1767, 2001.
18. Lenzen S, Formanek H, and Panten U. Signal function of metabolism of neutral amino acids and 2-keto acids for initiation of insulin secretion. J Biol Chem 257: 6631-6633, 1982.
19. Lenzen S, Schmidt W, and Panten U. Transamination of neutral amino acids and 2-keto acids in pancreatic B-cell mitochondria. J Biol Chem 260: 12629-12634, 1985.
20. Loh C, Shaw KT, Carew J, Viola JP, Luo C, Perrino BA, and Rao A. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J Biol Chem 271: 10884-10891, 1996.
21. Malaisse WJ, Sener A, Malaisse-Legae F, Hutton JC, and Christophe J. The stimulus-secretion coupling of amino acid-induced insulin release. Metabolic interaction of L-glutamine and 2-ketoisocaproate in pancreatic islets. Biochim Biophys Acta 677: 39-49, 1981.
22. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241, 1996.
23. Matschinsky FM. Regulation of pancreatic β-cell glucokinase: from basics to therapeutics. Diabetes 51, Suppl 3: S394-S404, 2002.
24. Meglasson MD and Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev 2: 163-214, 1986.
25. Miwa I, Mita Y, Murata T, Okuda J, Sugiura M, Hamada Y, and Chiba T. Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Enzyme Protein 48: 135-142, 1994-1995.
26. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, and Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25: 583-592, 2002.
27. Oetjen E, Baun D, Beimesche S, Krause D, Cierny I, Blume R, Dickel C, Wehner S, and Knepel W. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice. Mol Pharmacol 63: 1289-1295, 2003.
28. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, and O'Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357: 692-694, 1992.
29. Patterson GH, Knobel SM, Arkhammar P, Thastrup O, and Piston DW. Separation of the glucose-stimulated cytoplasmic and mitochondrial NAD(P)H responses in pancreatic islet β cells. Proc Natl Acad Sci USA 97: 5203-5207, 2000.
30. Paty BW, Harmon JS, Marsh CL, and Robertson RP. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 73: 353-357, 2002.
31. Polastri L, Galbiati F, Bertuzzi F, Fiorina P, Nano R, Gregori S, Aldrighetti L, Pozza G, Secchi A, Adorini L, and Davalli AM. Secretory defects induced by immunosuppressive agents on human pancreatic β-cells. Acta Diabetol 39: 229-233, 2002.
32. Redmon JB, Olson LK, Armstrong MB, Greene MJ, and Robertson RP. Effects of tacrolimus (FK-506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98: 2786-2793, 1996.
33. Rorsman P. The pancreatic β-cell as a fuel sensor: an electrophysiologist's viewpoint. Diabetologia 40: 487-495, 1997.
34. Sawada S, Suzuki G, Kawase Y, and Takaku F. Novel immunosuppressive agent, FK-506. In vitro effects on the cloned T cell activation. J Immunol 139: 1797-1803, 1987.
35. Sener A, Pipeleers DG, Levy J, and Malaisse WJ. The stimulus-secretion coupling of glucose-induced insulin release. XXVI. Are the secretory and fuel functions of glucose dissociable by iodoacetate? Metabolism 27: 1505-1517, 1978.
36. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, and Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238, 2000.
37. Shaw KT, Ho AM, Raghavan A, Kim J, Jain J, Park J, Sharma S, Rao A, and Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 92: 11205-11209, 1995.
38. Shiraishi A, Yamada Y, Tsuura Y, Fujimoto S, Tsukiyama K, Mukai E, Toyoda Y, Miwa I, and Seino Y. A novel glucokinase regulator in pancreatic β cells: precursor of propionyl-CoA carboxylase β subunit interacts with glucokinase and augments its activity. J Biol Chem 276: 2325-2328, 2001.
39. Sweet IR, Li G, Najafi H, Berner D, and Matschinsky FM. Effect of a glucokinase inhibitor on energy production and insulin release in pancreatic islets. Am J Physiol Endocrinol Metab 271: E606-E625, 1996.
40. 2+-dependent exocytosis in pancreatic beta cells. Proc Natl Acad Sci USA 96: 760-765, 1999.
41. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, and Iida M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 145: 2264-2272, 2004.
42. Velho G, Froguel P, Clement K, Pueyo ME, Rakotoambinina B, Zouali H, Passa P, Cohen D, and Robert JJ. Primary pancreatic β-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet 340: 444-448, 1992.